Werewolf Therapeutics, Inc.
HOWL
$0.71
$0.0568.56%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -90.55% | -86.84% | -62.57% | -22.26% | 21.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -90.55% | -86.84% | -62.57% | -22.26% | 21.60% |
| Cost of Revenue | 36.45% | 5.10% | -3.41% | -22.45% | -23.65% |
| Gross Profit | -170.02% | -126.67% | -61.45% | 22.58% | 45.12% |
| SG&A Expenses | 3.95% | 3.97% | 2.01% | -2.29% | 0.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.87% | 4.74% | -1.73% | -16.42% | -16.58% |
| Operating Income | -81.70% | -62.59% | -32.56% | 14.12% | 27.75% |
| Income Before Tax | -88.70% | -66.56% | -31.20% | 17.58% | 30.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -88.70% | -66.56% | -31.20% | 17.58% | 30.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -88.70% | -66.56% | -31.20% | 17.58% | 30.56% |
| EBIT | -81.70% | -62.59% | -32.56% | 14.12% | 27.75% |
| EBITDA | -85.29% | -65.07% | -33.51% | 15.23% | 29.50% |
| EPS Basic | -55.05% | -34.88% | -5.38% | 34.32% | 44.23% |
| Normalized Basic EPS | -53.86% | -33.75% | -4.38% | 34.33% | 44.24% |
| EPS Diluted | -57.83% | -37.51% | -7.66% | 34.32% | 44.23% |
| Normalized Diluted EPS | -53.42% | -33.33% | -4.02% | 34.33% | 44.24% |
| Average Basic Shares Outstanding | 21.57% | 20.97% | 20.26% | 21.65% | 23.53% |
| Average Diluted Shares Outstanding | 21.93% | 21.35% | 20.66% | 21.65% | 23.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
